CY1122796T1 - Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων - Google Patents

Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων

Info

Publication number
CY1122796T1
CY1122796T1 CY20191100190T CY191100190T CY1122796T1 CY 1122796 T1 CY1122796 T1 CY 1122796T1 CY 20191100190 T CY20191100190 T CY 20191100190T CY 191100190 T CY191100190 T CY 191100190T CY 1122796 T1 CY1122796 T1 CY 1122796T1
Authority
CY
Cyprus
Prior art keywords
adenos
pharmaceutical forms
improved pharmaceutical
dosage forms
improved
Prior art date
Application number
CY20191100190T
Other languages
Greek (el)
English (en)
Inventor
Janik ADRIAANSEN
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122796(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of CY1122796T1 publication Critical patent/CY1122796T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20191100190T 2013-09-19 2019-02-13 Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων CY1122796T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13185200 2013-09-19
PCT/EP2014/069654 WO2015040002A1 (en) 2013-09-19 2014-09-16 Improved adenovirus formulations
EP14766474.2A EP3046536B1 (en) 2013-09-19 2014-09-16 Improved adenovirus formulations

Publications (1)

Publication Number Publication Date
CY1122796T1 true CY1122796T1 (el) 2021-05-05

Family

ID=49212683

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100190T CY1122796T1 (el) 2013-09-19 2019-02-13 Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων

Country Status (33)

Country Link
US (3) US9974737B2 (enExample)
EP (1) EP3046536B1 (enExample)
JP (1) JP6013654B2 (enExample)
KR (1) KR102258348B1 (enExample)
CN (2) CN111514314A (enExample)
AP (1) AP2016009154A0 (enExample)
AU (1) AU2014323230B2 (enExample)
BR (1) BR112016005761B1 (enExample)
CA (1) CA2923352C (enExample)
CL (1) CL2016000621A1 (enExample)
CY (1) CY1122796T1 (enExample)
DK (1) DK3046536T3 (enExample)
EA (1) EA036046B1 (enExample)
ES (1) ES2711115T3 (enExample)
HR (1) HRP20182159T1 (enExample)
HU (1) HUE041791T2 (enExample)
IL (1) IL244572A (enExample)
LT (1) LT3046536T (enExample)
ME (1) ME03324B (enExample)
MX (1) MX369156B (enExample)
MY (1) MY181190A (enExample)
NZ (1) NZ717156A (enExample)
PE (1) PE20160527A1 (enExample)
PH (1) PH12016500316B1 (enExample)
PL (1) PL3046536T3 (enExample)
PT (1) PT3046536T (enExample)
RS (1) RS58393B1 (enExample)
SG (1) SG11201601181SA (enExample)
SI (1) SI3046536T1 (enExample)
SM (1) SMT201900092T1 (enExample)
TR (1) TR201900274T4 (enExample)
WO (1) WO2015040002A1 (enExample)
ZA (1) ZA201601919B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041659T2 (hu) 2013-04-25 2019-05-28 Janssen Vaccines & Prevention Bv Stabilizált oldható pre-fúziós RSV F polipeptidek
WO2015038958A1 (en) 2013-09-13 2015-03-19 California Institute Of Technology Selective recovery
ES2711115T3 (es) * 2013-09-19 2019-04-30 Janssen Vaccines & Prevention Bv Formulaciones de adenovirus mejoradas
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
BR112018006488B1 (pt) * 2015-10-06 2024-03-12 Janssen Vaccines & Prevention B.V. Métodos para prevenir a degradação induzida por plástico de biológicos
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
SG11201807913XA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
BR112018074483A2 (pt) 2016-05-30 2019-03-19 Janssen Vaccines & Prevention B.V. proteínas f do rsv pré-fusão estabilizadas
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
CA3114621A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CR20210306A (es) 2018-11-13 2021-07-22 Janssen Vaccines & Prevention Bv Proteínas f de prefusión del vrs estabilizadas
AU2020206984A1 (en) * 2019-01-09 2021-07-15 Ziccum Ab Stabilized non-enveloped virus compositions
US20240033334A1 (en) * 2020-12-04 2024-02-01 Gritstone Bio, Inc. Compositions and methods of use thereof
MX2024000472A (es) * 2021-07-08 2024-02-12 Biocad Joint Stock Co Composicion farmaceutica de virus no encapsulado.
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
CN120265310A (zh) * 2022-10-11 2025-07-04 梅里特斯英国第二有限公司 Aav基因疗法的配制品
WO2025218651A1 (zh) * 2024-04-15 2025-10-23 康希诺生物股份公司 一种重组腺病毒载体疫苗制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
DK1133316T3 (da) * 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1263461A4 (en) * 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
JP2005517394A (ja) * 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
SI1456377T1 (sl) * 2001-12-20 2019-09-30 Merck Sharp & Dohme Corp. Sestavki SYN3 in postopki
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
EP1573012B1 (en) 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
NZ543970A (en) * 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
EP1646684A4 (en) * 2003-06-30 2010-09-29 Canji Inc POLYMER ENCAPSULATION OF ADENOVIRES
US20070148765A1 (en) * 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
US8137966B2 (en) * 2004-03-04 2012-03-20 Dainippon Sumitomo Pharma Co., Ltd. Rat embryonic stem cell
MX2007005256A (es) 2004-11-16 2008-03-11 Crucell Holland Bv Vacunas multivalentes que comprenden vectores virales recombinantes.
CN1883707A (zh) * 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
GB0715723D0 (en) * 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
EP2473191B1 (en) * 2009-09-04 2017-08-23 XOMA Technology Ltd. Antibody coformulations
GB201002419D0 (en) 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
WO2012110971A2 (en) 2011-02-17 2012-08-23 Promed Exports Pvt. Ltd. Method and composition to retard sorption of preservatives to plastics
ES2711115T3 (es) 2013-09-19 2019-04-30 Janssen Vaccines & Prevention Bv Formulaciones de adenovirus mejoradas
CN104027815A (zh) 2014-06-12 2014-09-10 中国农业科学院兰州畜牧与兽药研究所 一种丹参酮包合液及其制备方法和应用
BR112018006488B1 (pt) 2015-10-06 2024-03-12 Janssen Vaccines & Prevention B.V. Métodos para prevenir a degradação induzida por plástico de biológicos

Also Published As

Publication number Publication date
AP2016009154A0 (en) 2016-04-30
AU2014323230A1 (en) 2016-03-17
US20180235871A1 (en) 2018-08-23
SG11201601181SA (en) 2016-04-28
EP3046536B1 (en) 2018-11-28
US11484494B2 (en) 2022-11-01
SI3046536T1 (sl) 2019-05-31
CN105530917B (zh) 2020-06-05
RS58393B1 (sr) 2019-04-30
US9974737B2 (en) 2018-05-22
US20160199426A1 (en) 2016-07-14
WO2015040002A1 (en) 2015-03-26
HRP20182159T1 (hr) 2019-02-22
HUE041791T2 (hu) 2019-05-28
MX369156B (es) 2019-10-30
BR112016005761B1 (pt) 2022-09-20
DK3046536T3 (en) 2019-03-11
CN111514314A (zh) 2020-08-11
MY181190A (en) 2020-12-21
BR112016005761A2 (enExample) 2017-08-01
IL244572A0 (en) 2016-04-21
JP2016530220A (ja) 2016-09-29
CA2923352C (en) 2022-05-03
CA2923352A1 (en) 2015-03-26
KR102258348B1 (ko) 2021-05-31
CN105530917A (zh) 2016-04-27
PT3046536T (pt) 2019-02-25
SMT201900092T1 (it) 2019-02-28
NZ717156A (en) 2022-04-29
ME03324B (me) 2019-10-20
US20190240146A1 (en) 2019-08-08
AU2014323230B2 (en) 2017-05-25
LT3046536T (lt) 2019-03-12
ZA201601919B (en) 2017-06-28
PL3046536T3 (pl) 2019-06-28
PH12016500316A1 (en) 2016-05-02
ES2711115T3 (es) 2019-04-30
KR20160055180A (ko) 2016-05-17
EA036046B1 (ru) 2020-09-18
TR201900274T4 (tr) 2019-02-21
EA201690613A1 (ru) 2016-08-31
PH12016500316B1 (en) 2019-02-01
JP6013654B2 (ja) 2016-10-25
IL244572A (en) 2017-02-28
US10272032B2 (en) 2019-04-30
PE20160527A1 (es) 2016-05-20
CL2016000621A1 (es) 2016-11-25
MX2016003414A (es) 2016-06-30
EP3046536A1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
MX377710B (es) Anticuerpos monoclonales contra bcma.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
UY34885A (es) Proteínas de unión anti-mesotelina
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
BR112016023628A2 (pt) composições farmacêuticas.
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
LT3494962T (lt) Skysta inhaliavimo kompozicija, apimanti rpl554
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
HUE054551T2 (hu) Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
UA115373C2 (uk) Стабільний рідкий склад amg 416 (велкалсетиду)
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
ES2651188T8 (es) Composición líquida fotopolimerizable
DK3215223T3 (da) Buprenorphindoseringsskemaer
IL269169A (en) Novel dosage form
UA116372C2 (uk) Частинки резинату фенілефрину